HK1221636A1 - 阿片樣物質製劑 - Google Patents

阿片樣物質製劑

Info

Publication number
HK1221636A1
HK1221636A1 HK16109379.4A HK16109379A HK1221636A1 HK 1221636 A1 HK1221636 A1 HK 1221636A1 HK 16109379 A HK16109379 A HK 16109379A HK 1221636 A1 HK1221636 A1 HK 1221636A1
Authority
HK
Hong Kong
Prior art keywords
opioid formulations
opioid
formulations
Prior art date
Application number
HK16109379.4A
Other languages
English (en)
Inventor
Fredrik Tiberg
Lan Harwigsson
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1221636(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of HK1221636A1 publication Critical patent/HK1221636A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
HK16109379.4A 2012-07-26 2016-08-05 阿片樣物質製劑 HK1221636A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28

Publications (1)

Publication Number Publication Date
HK1221636A1 true HK1221636A1 (zh) 2017-06-09

Family

ID=53487482

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15106598.6A HK1205948A1 (zh) 2012-07-26 2015-07-10 阿片樣製劑
HK16109379.4A HK1221636A1 (zh) 2012-07-26 2016-08-05 阿片樣物質製劑

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15106598.6A HK1205948A1 (zh) 2012-07-26 2015-07-10 阿片樣製劑

Country Status (20)

Country Link
US (1) US20240075024A1 (zh)
JP (1) JP6417327B2 (zh)
CN (1) CN109010255B (zh)
AU (3) AU2016244271B2 (zh)
CL (1) CL2015000197A1 (zh)
CY (1) CY1124016T1 (zh)
DK (1) DK2877155T3 (zh)
EA (1) EA034855B1 (zh)
ES (1) ES2837803T3 (zh)
HK (2) HK1205948A1 (zh)
HR (1) HRP20210068T1 (zh)
HU (1) HUE053273T2 (zh)
IL (3) IL296882A (zh)
LT (1) LT2877155T (zh)
MX (1) MX361873B (zh)
MY (1) MY189481A (zh)
NZ (2) NZ735248A (zh)
PE (1) PE20150672A1 (zh)
PT (1) PT2877155T (zh)
SG (2) SG11201500554XA (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
WO2019071243A1 (en) * 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
CN117999079A (zh) * 2021-08-20 2024-05-07 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
ES2343641T3 (es) * 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
EP1848403B8 (en) * 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
GB2481018B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
AU2017279657B2 (en) 2018-11-15
AU2016244271B2 (en) 2018-01-18
EA201590202A1 (ru) 2015-07-30
BR112015001548A2 (pt) 2017-07-04
JP2015522649A (ja) 2015-08-06
ES2837803T3 (es) 2021-07-01
HK1205948A1 (zh) 2015-12-31
MX2015001033A (es) 2015-04-09
DK2877155T3 (da) 2021-01-18
NZ704012A (en) 2017-09-29
AU2019200982B2 (en) 2019-07-18
IL289157A (en) 2022-02-01
SG10201703964TA (en) 2017-06-29
PE20150672A1 (es) 2015-05-21
LT2877155T (lt) 2021-02-25
AU2016244271A1 (en) 2016-10-27
HUE053273T2 (hu) 2021-06-28
IL236762A0 (en) 2015-03-31
CN109010255B (zh) 2022-10-21
MY189481A (en) 2022-02-16
CN109010255A (zh) 2018-12-18
PT2877155T (pt) 2020-12-18
US20240131021A1 (en) 2024-04-25
NZ735248A (en) 2018-10-26
SG11201500554XA (en) 2015-02-27
US20240075024A1 (en) 2024-03-07
IL296882A (en) 2022-12-01
HRP20210068T1 (hr) 2021-03-05
CL2015000197A1 (es) 2015-11-13
CY1124016T1 (el) 2022-05-27
MX361873B (es) 2018-12-18
AU2017279657A1 (en) 2018-01-18
EA034855B1 (ru) 2020-03-30
AU2019200982A1 (en) 2019-02-28
JP6417327B2 (ja) 2018-11-07

Similar Documents

Publication Publication Date Title
GB201304182D0 (en) No details
GB201403961D0 (en) No details
PL2877155T3 (pl) Formulacje opioidowe
GB201411220D0 (en) No details
HK1202445A1 (zh) 新製劑
IL289157A (en) Opioid compounds
HK1205679A1 (zh) 尼古丁製劑
PL2908835T3 (pl) Stabilne formulacje
GB201313844D0 (en) No details
PL2908859T3 (pl) Formulacje arypiprazolu
GB201403415D0 (en) No details
GB201110278D0 (en) Formulations
IL234771B (en) Nicotine formulation
GB201206178D0 (en) Formulations
GB201211247D0 (en) Improved formulation
GB201322955D0 (en) No details
GB201400108D0 (en) No details
GB201302155D0 (en) No details
GB201300109D0 (en) No details
GB201310646D0 (en) No details
GB201220529D0 (en) No details available
GB201107626D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations